title: Do different aminobisphosphonates have similar preventive effect on experimental thyroid hormone-induced osteopenia in rats?
abstract: We compared similar doses of three different aminobisphosphonates (BP): olpadronate (OPD), pamidronate (APD), and alendronate (ALE) on osteopenia induced by thyroxine (T4)-treatment in OVX and SHAM adult rats. Female Sprague Dawley rats (259 +/- 8 g) were treated with vehicle (SHAM+Vh and OVX+Vh), 250 microg T4/kg/day (SHAM+T4 and OVX+T4), 0.3 mg OPD/kg/day (SHAM+OPD and OVX+OPD), 0.2 mg ALE/kg/day (SHAM+ALE and OVX+ALE), 1.5 mg APD/kg/day (SHAM+APD and OVX+APD), T4+OPD (SHAM+T4+OPD and OVX+T4+OPD), T4+ALE (SHAM+T4+ALE and OVX+T4+ALE), and T4 +APD (SHAM+T4+APD and OVX+T4+APD) during a 5-week period. At the onset and at the end of the experiment, total skeleton bone mineral density (BMD) was assessed in vivo by DXA. Lumbar spine and proximal tibia BMDs were evaluated. T4 treatment to SHAM rats did not modify BGP levels significantly: neither did ovariectomy. T4 treatment to OVX rats significantly increased bone-gla-protein (BGP) levels compared with the other studied groups (P < 0.05). BP treatment reduced BGP levels to values significantly lower than SHAM rats (P < 0.05) and reduced bone alkaline phosphatase in SHAM groups (P < 0.05) but no changes were found in OVX groups. The increased D-Pyr excretion observed in SHAM+T4 rats (P = 0.056), OVX+Vh (P < 0.05), and OVX+T4 group (P < 0.001) compared with the SHAM+Vh rats was prevented by the BP treatment. OVX+Vh rats had total skeleton and proximal tibia BMD, and OVX+T4 group had total skeleton, spine, and proximal tibia BMD significantly lower than the SHAM+Vh group. BP treatment was also found to prevent this reduction. The reduced bone resorption and the prevention of bone loss showed no differences among very close, potentially equivalent doses of the three aminoBPs used. Consequently, treatment with very close similar doses of APD, ODP, and ALE prevented bone resorption and bone changes with the same efficacy.
authors.affiliation: The National Research Council (CONICET) in the Sección Osteopatías Médicas, Hospital de Clínicas, Jose de San Martin Facultad de Medicina, Universidad de Buenos Aires, Argentina.
authors.forename: S
authors.initials: S
authors.lastname: Zeni
authors.forename: C
authors.initials: C
authors.lastname: Gomez-Acotto
authors.forename: C
authors.initials: C
authors.lastname: Mautalen
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000517:prevention & control*; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D000077268:Pamidronate; D051381:Rats; D017207:Rats, Sprague-Dawley; D013974:Thyroxine
chemical_list: D004164:Diphosphonates; C055774:olpadronic acid; D000077268:Pamidronate; D013974:Thyroxine; D019386:Alendronate